Bivalirudin: a new approach to anticoagulation
Pharmacology review published in Heart Dis (2001)
Abstract
Bivalirudin is one of the first of a new class of anticoagulants known as direct thrombin inhibitors. These drugs are able to overcome many of the shortcomings of traditional heparin anticoagulation by virtue of this unique mechanism of action. Bivalirudin is a semisynthetic derivative of hirudin, a modified component of leech saliva. Hirudin has been plagued by bleeding complications, likely due to its high affinity for thrombin. Bivalirudin has lower thrombin affinity than hirudin and therefore is believed to be a much safer compound. Bivalirudin has been shown to be a very effective anticoagulant in laboratory models, though its clinical efficacy remains to be fully proven. Bivalirudin has been studied in the setting of coronary angioplasty, unstable angina, and acute myocardial infarction and has shown some promise in many of these settings, particularly in preventing complications of percutaneous coronary interventions. Bivalirudin has consistently shown less major bleeding compared with standard heparin, although limitations in study methodologies somewhat hinder an accurate interpretation of this finding. Larger-scale studies are indicated and are currently being performed, the results of which will more definitively define the role of bivalirudin for the treatment of cardiovascular disease.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Bivalirudin, a semisynthetic hirudin derivative with lower thrombin affinity, was developed to retain hirudin's direct thrombin-inhibition mechanism while reducing bleeding risk. Reviews clinical evidence in coronary angioplasty, unstable angina, and acute MI.
Por qué esto importa para la hirudoterapia
Esta revisión examinó la bivalirudina, un derivado semisintético de la hirudina originalmente aislada de la saliva de la sanguijuela, como anticoagulante inhibidor directo de la trombina para indicaciones cardiovasculares que incluyen la angioplastia coronaria, la angina inestable y el infarto agudo de miocardio. Es directamente relevante para el ámbito de la ASH porque traza la trayectoria de un anticoagulante clínico hasta el secretoma de la sanguijuela, ilustrando cómo las moléculas inspiradas en la hirudina han avanzado hacia la farmacoterapia cardiovascular. El resumen señala que la bivalirudina presenta menor afinidad por la trombina en comparación con la hirudina, lo que potencialmente ofrece una mejor seguridad, y reporta de forma consistente menos sangrado mayor frente a la heparina. Sin embargo, se trata de una revisión de un derivado farmacéutico en fase temprana —no de un estudio sobre hirudoterapia o aplicación de sanguijuelas vivas— y el resumen indica explícitamente que la eficacia clínica 'aún no se ha demostrado por completo' y que en el momento de la publicación todavía se estaban llevando a cabo estudios de mayor escala.
Citación
Bivalirudin: a new approach to anticoagulation.
Nawarskas JJ, Anderson JR · Heart disease (Hagerstown, Md.), 2001
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: 18 de junio de 2026